|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLCO1A2 |
Gene summary for SLCO1A2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLCO1A2 | Gene ID | 6579 |
| Gene name | solute carrier organic anion transporter family member 1A2 | |
| Gene Alias | OATP | |
| Cytomap | 12p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024RAT5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6579 | SLCO1A2 | C38 | Human | Oral cavity | OSCC | 1.66e-10 | 7.27e-01 | 0.172 |
| 6579 | SLCO1A2 | C06 | Human | Oral cavity | OSCC | 6.22e-04 | 4.95e-01 | 0.2699 |
| 6579 | SLCO1A2 | C08 | Human | Oral cavity | OSCC | 3.71e-12 | 2.26e-01 | 0.1919 |
| 6579 | SLCO1A2 | LN38 | Human | Oral cavity | OSCC | 1.18e-06 | 9.00e-01 | 0.168 |
| 6579 | SLCO1A2 | SYSMH1 | Human | Oral cavity | OSCC | 1.77e-03 | 8.17e-02 | 0.1127 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLCO1A2 | SNV | Missense_Mutation | novel | c.1843C>T | p.Pro615Ser | p.P615S | P46721 | protein_coding | tolerated(0.07) | benign(0.443) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| SLCO1A2 | SNV | Missense_Mutation | c.1069N>G | p.Leu357Val | p.L357V | P46721 | protein_coding | tolerated(0.29) | benign(0.393) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLCO1A2 | SNV | Missense_Mutation | novel | c.608C>A | p.Ala203Asp | p.A203D | P46721 | protein_coding | deleterious(0.02) | possibly_damaging(0.694) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLCO1A2 | SNV | Missense_Mutation | c.1561A>G | p.Ser521Gly | p.S521G | P46721 | protein_coding | tolerated(0.17) | benign(0.071) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SLCO1A2 | SNV | Missense_Mutation | novel | c.475N>A | p.Val159Met | p.V159M | P46721 | protein_coding | deleterious(0.02) | benign(0.297) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SLCO1A2 | deletion | In_Frame_Del | novel | c.1748_1762delGTGGTGAGTCAGGGG | p.Cys583_Ala588delinsSer | p.C583_A588delinsS | P46721 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLCO1A2 | SNV | Missense_Mutation | novel | c.330N>A | p.Met110Ile | p.M110I | P46721 | protein_coding | tolerated(0.11) | possibly_damaging(0.838) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| SLCO1A2 | SNV | Missense_Mutation | c.1148N>A | p.Thr383Asn | p.T383N | P46721 | protein_coding | tolerated(1) | benign(0.013) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| SLCO1A2 | SNV | Missense_Mutation | c.1147N>T | p.Thr383Ser | p.T383S | P46721 | protein_coding | tolerated(0.9) | benign(0.088) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| SLCO1A2 | SNV | Missense_Mutation | rs763423819 | c.1549T>C | p.Ser517Pro | p.S517P | P46721 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | TESTOSTERONE | TESTOSTERONE | 8779895 | |
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 135652711 | RIFAMPIN | |
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | HORMONES | 8779894 | ||
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | hmg coa reductase inhibitors | |||
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178101291 | ||
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | rocuronium | ROCURONIUM | 28409297 | |
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | methotrexate | METHOTREXATE | 21317831 | |
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | 178101458 | |||
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | imatinib | IMATINIB | 21633340 | |
| 6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | 178101232 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |